US biotech bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief commercial officer. 15 February 2018
Immuno-oncology therapy Opdivo (nivolumab) has received registration by Australia’s Therapeutic Goods Administration (TGA) as a monotherapy for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy, says US pharma major Bristol-Myers Squibb. 15 February 2018
Beijing Innocare has completed a $55 million funding round, led by healthcare investment firm Vivo Capital. The firm is focused on developing treatments for cancer and autoimmune diseases. 13 February 2018
Horizon Discovery, a specialist in gene editing and gene modulation technologies, has entered into a non-exclusive out-licensing agreement with a USA-based immuno-oncology therapeutics developer. 13 February 2018
UK-based EUSA Pharma has received good news on Fotivda (tivozanib), the product that it holds exclusive commercialization rights to in renal cell carcinoma (RCC) in Europe and other ex-North America territories. 12 February 2018
Japanese pharma company Eisai can point to another accolade for its drug Lenvima/Kisplyx (lenvatinib) as it seeks regulatory approval of the drug in hepatocellular carcinoma (HCC). 12 February 2018
Novo Nordisk has launched Rebinyn (coagulation factor IX recombinant) in the USA. The Danish firm’s extended half-life hemophilia B treatment was approved by the US FDA in June last year. 9 February 2018
The US Food and Drug Administration (FDA) has approved a new indication for Zytiga (abiraterone acetate) in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). 8 February 2018
The creation of Syndesi Therapeutics was announced on Thursday as the result of a partnership between UCB and a syndicate of Belgian and international investors. 8 February 2018
BioDiscovery, a leading global investor in biotechnology and medical devices managed by Edmond De Rothschild Investment Partners, has closed the subscription period to its fifth fund, raising 345 million euros ($430 million). 8 February 2018
The European Medicines Agency (EMA) has updated its procedural advice on the evaluation of advanced therapy medicinal products (ATMPs). 2 February 2018
Ferring Pharmaceuticals has been awarded US FDA approval for its Zomacton recombinant human growth hormone (GH) as a treatment for GH deficiency in adults. 1 February 2018
Shanghai-based WuXi Biologics has expanded a collaboration with Texas, USA-based Aravive Biologics following the firm’s US regulatory filing for oncology candidate AVB-S6-500. 31 January 2018
The USA’s Puma Biotechnology has agreed a deal for Medison Pharma to seek regulatory approval for and commercialize breast cancer therapy Nerlynx in its native Israel. 31 January 2018
The USA’s Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Hemlibra (emicizumab), developed by Roche subsidiary Genentech. 30 January 2018
The US Securities and Exchange Commission has filed a lawsuit relating to what it calls ‘highly suspicious trading’ by one or multiple shareholders in Bioverativ just prior to last week’s announcement that it was to be taken over by Sanofi. 29 January 2018
In a surprise announcement this morning, Belgium biotech firm Ablynx revealed that it has entered into a definitive agreement to be acquired by French pharma major Sanofi. 29 January 2018
The Taiwanese subsidiary of Japan’s Ono Pharmaceutical has won approval for an extension to the label for Opdivo to treat advanced or recurrent gastric cancer patients in the second-line setting. 25 January 2018
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024